

It Takes 2 Simple Tests to Detect CKD and Cardiovascular Risk

The Boehringer Ingelheim and Eli Lilly and Company Alliance is committed to kidney health and a holistic approach to prioritizing people's overall cardiovascular, renal, and metabolic (CRM) health. To educate on the unknown nature of chronic kidney disease (CKD) among at-risk patients and healthcare professionals, the Alliance launched *It Takes 2*, a health initiative that aims to elevate the importance of complete testing and early diagnosis of CKD. Diabetes and high blood pressure are responsible for up to two-thirds of kidney disease cases, and kidney disease often has no symptoms in its early stages. By adding UACR urine testing to screen for kidney disease, healthcare professionals, especially primary care physicians, will be better prepared to stage and stratify risk of CKD progression. Along with the eGFR blood test, the UACR urine test may also help uncover the risk of cardiovascular disease.

Additional information on the importance of using two tests to screen for CKD and cardiovascular risk is available at CKDtesting.com

IT TAKES 2™



Boehringer
Ingelheim

Lilly